hydroxyurea has been researched along with Thrombopenia in 47 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea is a cytostatic agent used in patients with myeloproliferative disorders that may produce nail hyperpigmentation, most frequently longitudinal melanonychia." | 7.70 | Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. ( de Unamuno, P; Hernández-Martín, A; Ros-Forteza, S, 1999) |
| "A 38-year-old man with idiopathic hypereosinophilic syndrome had an inadequate response to steroids and severe side effects from hydroxyurea treatment, which necessitated withdrawal of the treatment." | 7.68 | Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. ( de Vries, EG; Smit, AJ; van Essen, LH, 1991) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 7.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Paediatric primary myelofibrosis (PMF) is exceedingly rare and distinct compared with adult PMF." | 5.91 | Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea. ( Khera, S; Misra, P; Singh, K; Tripathi, P, 2023) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 5.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera." | 5.20 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. ( Durrant, S; Garrett, W; Griesshammer, M; Habr, D; Harrison, CN; He, S; Jones, MM; Kiladjian, JJ; Li, J; Masszi, T; Mesa, R; Pane, F; Passamonti, F; Pirron, U; Vannucchi, AM; Verstovsek, S; Zachee, P, 2015) |
| "Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB)." | 3.72 | Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. ( Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C, 2004) |
| "Hydroxyurea is a cytostatic agent used in patients with myeloproliferative disorders that may produce nail hyperpigmentation, most frequently longitudinal melanonychia." | 3.70 | Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. ( de Unamuno, P; Hernández-Martín, A; Ros-Forteza, S, 1999) |
| "A 38-year-old man with idiopathic hypereosinophilic syndrome had an inadequate response to steroids and severe side effects from hydroxyurea treatment, which necessitated withdrawal of the treatment." | 3.68 | Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. ( de Vries, EG; Smit, AJ; van Essen, LH, 1991) |
| "The effect of hydroxyurea in 35 patients with chronic granulocytic leukemia (CGL), who either had entered an accelerated phase of the disease or had experienced excessive myelosuppression following alkylating agents, was studied." | 3.65 | Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia. ( Cannellos, GP; Schwartz, JH, 1975) |
| "Paediatric primary myelofibrosis (PMF) is exceedingly rare and distinct compared with adult PMF." | 1.91 | Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea. ( Khera, S; Misra, P; Singh, K; Tripathi, P, 2023) |
| "Treatment with WEB 2086, alone or in combination with Zileuton, did not inhibit LPS-mediated hepatic neutrophil infiltration or liver injury, as assessed by histologic evaluation and increases in plasma alanine aminotransferase activity." | 1.30 | Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. ( Bailie, MB; Fink, GD; Pearson, JM; Roth, RA, 1997) |
| "Thrombocytopenia was significant but transient and was dose-limiting only for patients who had received prior therapy." | 1.28 | Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model. ( Albain, KS; Erickson, LC; Fisher, RI; Stiff, PJ; Swinnen, LJ, 1990) |
| "Hydroxyurea is an effective agent in the treatment of PV, but continued assessment of its mutagenic potential is necessary." | 1.27 | Treatment of polycythemia vera with hydroxyurea. ( Berk, PD; Donovan, PB; Goldberg, JD; Kaplan, ME; Knospe, WH; Laszlo, J; Mack, K; Najean, Y; Silberstein, EB; Tatarsky, I, 1984) |
| "Hydroxyurea was administered by means of two schedules designed to provide continuous 72-hour exposure of tumor cells to therapeutic drug levels." | 1.26 | Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. ( Belt, RJ; Haas, CD; Kennedy, J; Taylor, S, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (44.68) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 5 (10.64) | 29.6817 |
| 2010's | 9 (19.15) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, DQ | 1 |
| Zhao, WS | 1 |
| Yin, CX | 1 |
| He, H | 1 |
| Lin, R | 1 |
| Zhao, K | 1 |
| Ye, JY | 1 |
| Liu, QF | 1 |
| Dai, M | 1 |
| Chang, L | 1 |
| Duan, MH | 1 |
| Khera, S | 1 |
| Misra, P | 1 |
| Singh, K | 1 |
| Tripathi, P | 1 |
| Verstovsek, S | 2 |
| Passamonti, F | 2 |
| Rambaldi, A | 1 |
| Barosi, G | 1 |
| Rosen, PJ | 1 |
| Rumi, E | 1 |
| Gattoni, E | 1 |
| Pieri, L | 1 |
| Guglielmelli, P | 1 |
| Elena, C | 1 |
| He, S | 2 |
| Contel, N | 1 |
| Mookerjee, B | 1 |
| Sandor, V | 1 |
| Cazzola, M | 1 |
| Kantarjian, HM | 1 |
| Barbui, T | 1 |
| Vannucchi, AM | 2 |
| Kiladjian, JJ | 1 |
| Griesshammer, M | 1 |
| Masszi, T | 1 |
| Durrant, S | 1 |
| Harrison, CN | 1 |
| Pane, F | 1 |
| Zachee, P | 1 |
| Mesa, R | 1 |
| Jones, MM | 1 |
| Garrett, W | 1 |
| Li, J | 1 |
| Pirron, U | 1 |
| Habr, D | 1 |
| Rassnick, KM | 1 |
| Al-Sarraf, R | 1 |
| Bailey, DB | 1 |
| Chretin, JD | 1 |
| Phillips, B | 1 |
| Zwhalen, CH | 1 |
| Kälsch, H | 1 |
| Wieneke, H | 1 |
| Erbel, R | 1 |
| Zhang, Z | 1 |
| Wan, X | 1 |
| Liu, Y | 1 |
| Lin, X | 1 |
| Ni, Z | 1 |
| Yang, X | 1 |
| Zhang, L | 1 |
| Goerge, T | 1 |
| Schellong, G | 1 |
| Mesters, RM | 1 |
| Berdel, WE | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Herndon, JE | 1 |
| Coan, A | 1 |
| Gururangan, S | 1 |
| Peters, KB | 1 |
| McLendon, R | 1 |
| Sathornsumetee, S | 1 |
| Rich, JN | 1 |
| Lipp, ES | 1 |
| Janney, D | 1 |
| Friedman, HS | 1 |
| Williams, MW | 1 |
| Vishwanath, M | 1 |
| Yates, AM | 1 |
| Dedeken, L | 1 |
| Smeltzer, MP | 1 |
| Lebensburger, JD | 1 |
| Wang, WC | 1 |
| Robitaille, N | 1 |
| Ohashi, N | 1 |
| Yonemura, K | 1 |
| Sugiura, T | 1 |
| Isozaki, T | 1 |
| Togawa, A | 1 |
| Fujigaki, Y | 1 |
| Yamamoto, T | 1 |
| Hishida, A | 1 |
| Braester, A | 1 |
| GRIFFITH, KM | 1 |
| FERNBACH, DJ | 1 |
| HOWE, CD | 1 |
| SAMUELS, ML | 1 |
| DAVIS, P | 1 |
| Bastie, JN | 1 |
| Garcia, I | 1 |
| Terré, C | 1 |
| Cross, NC | 1 |
| Mahon, FX | 1 |
| Castaigne, S | 1 |
| Sheikh-Taha, M | 1 |
| Koussa, S | 1 |
| Taher, A | 1 |
| Zaccaria, E | 1 |
| Cozzani, E | 1 |
| Parodi, A | 1 |
| Cassileth, PA | 1 |
| Hyman, GA | 1 |
| Vogl, SE | 1 |
| Camacho, F | 1 |
| Kaplan, BH | 1 |
| Lerner, H | 1 |
| Cinberg, J | 1 |
| Stephens, RL | 1 |
| Vaughn, C | 1 |
| Lane, M | 1 |
| Costanzi, J | 1 |
| O'Bryan, R | 1 |
| Balcerzak, SP | 1 |
| Levin, H | 1 |
| Frank, J | 1 |
| Coltman, CA | 1 |
| Donovan, PB | 1 |
| Kaplan, ME | 1 |
| Goldberg, JD | 1 |
| Tatarsky, I | 1 |
| Najean, Y | 1 |
| Silberstein, EB | 1 |
| Knospe, WH | 1 |
| Laszlo, J | 1 |
| Mack, K | 1 |
| Berk, PD | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Douglass, HO | 1 |
| Muggia, F | 1 |
| Mittelman, A | 1 |
| Ebbe, S | 2 |
| Phalen, E | 1 |
| Belt, RJ | 1 |
| Haas, CD | 1 |
| Kennedy, J | 1 |
| Taylor, S | 1 |
| Vokes, EE | 1 |
| Haraf, DJ | 1 |
| Drinkard, LC | 1 |
| Hoffman, PC | 1 |
| Ferguson, MK | 1 |
| Vogelzang, NJ | 1 |
| Watson, S | 1 |
| Lane, NJ | 1 |
| Golomb, HM | 1 |
| Shepherd, PC | 1 |
| Richards, S | 1 |
| Allan, NC | 1 |
| Gardner, L | 1 |
| Grosso, LE | 1 |
| Miras Parra, FJ | 1 |
| Salvatierra Ossorio, J | 1 |
| Gómez Jiménez, FJ | 1 |
| de la Higuera Torres-Puchol, J | 1 |
| Pearson, JM | 1 |
| Bailie, MB | 1 |
| Fink, GD | 1 |
| Roth, RA | 1 |
| Hernández-Martín, A | 1 |
| Ros-Forteza, S | 1 |
| de Unamuno, P | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Simon, R | 1 |
| Carr, DT | 1 |
| van Wyk, CE | 1 |
| Tucker, RD | 1 |
| Sealy, R | 1 |
| Alberto, P | 1 |
| Barrelet, L | 1 |
| Chapuis, B | 1 |
| Garcia, B | 1 |
| Folan, DW | 1 |
| Schwartz, JH | 1 |
| Cannellos, GP | 1 |
| Nese, M | 1 |
| Smit, AJ | 1 |
| van Essen, LH | 1 |
| de Vries, EG | 1 |
| Albain, KS | 1 |
| Swinnen, LJ | 1 |
| Erickson, LC | 1 |
| Stiff, PJ | 1 |
| Fisher, RI | 1 |
| Moschella, SL | 1 |
| Greenwald, MA | 1 |
| Hellmann, K | 1 |
| Nissen, NI | 1 |
| Dano, K | 1 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Creasey, WA | 1 |
| Capizzi, RL | 1 |
| DeConti, RC | 1 |
| Gottlieb, JA | 1 |
| Frei, E | 1 |
| Luce, JK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)[NCT01243944] | Phase 3 | 222 participants (Actual) | Interventional | 2010-10-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 20.0 |
| Best Available Therapy | 0.9 |
Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32). (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 22.7 |
| Best Available Therapy | 0.9 |
Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10^9/L and a white blood cell count less than or equal to 10 X 10^9/L. (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 23.6 |
| Best Available Therapy | 8.0 |
Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 20.9 |
| Best Available Therapy | 0.9 |
Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 54.5 |
| Best Available Therapy | 1.8 |
Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ruxolitinib | 37.3 |
| Best Available Therapy | 0.9 |
Duration of spleen volume reduction is defined as the time from the first occurrence of a >=35% reduction from baseline in spleen volume until the date of the first documented progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.98 | 0.95 | 0.95 | 0.95 | 0.93 | 0.93 | 0.93 | 0.87 | 0.72 | NA | NA |
Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.97 | 0.92 | 0.91 | 0.91 | 0.87 | 0.84 | 0.84 | 0.82 | 0.79 | 0.77 | 0.73 | 0.73 | 0.73 | 0.73 |
Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression. (NCT01243944)
Timeframe: 256 Weeks
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 0.99 | 0.96 | 0.91 | 0.88 | 0.88 | 0.85 | 0.82 | 0.82 | 0.80 | 0.75 | 0.70 | 0.67 | 0.67 | 0.67 | 0.67 |
"Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).~Kaplan-Meier estimates are provided for duration of complete hematological remission." (NCT01243944)
Timeframe: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.88 | 0.83 | 0.74 | 0.74 | 0.69 | 0.69 | 0.65 | 0.65 | 0.55 | 0.55 | 0.55 | 0.55 | NA | NA |
"Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).~Kaplan-Meier estimates are provided for duration of primary response." (NCT01243944)
Timeframe: Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
| Intervention | probability (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16 weeks | 32 weeks | 48 weeks | 64 weeks | 80 weeks | 96 weeks | 112 weeks | 128 weeks | 144 weeks | 160 weeks | 176 weeks | 192 weeks | 208 weeks | 224 weeks | 240 weeks | 256 weeks | |
| Ruxolitinib | 1.00 | 1.00 | 0.92 | 0.92 | 0.92 | 0.88 | 0.84 | 0.84 | 0.84 | 0.79 | 0.79 | 0.74 | 0.74 | 0.74 | NA | NA |
Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization. (NCT01243944)
Timeframe: 48 Weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response rate | Partial response rate | |
| Best Available Therapy | 0.9 | 0.9 |
| Ruxolitinib | 7.3 | 50.9 |
Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria. (NCT01243944)
Timeframe: 32 Weeks
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response rate | Partial response rate | |
| Best Available Therapy | 0.9 | 18.8 |
| Ruxolitinib | 8.2 | 54.5 |
1 review available for hydroxyurea and Thrombopenia
| Article | Year |
|---|---|
[New principles of treatment in acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Central Nervous System Diseases; Child; Cyclophosphamide; | 1970 |
12 trials available for hydroxyurea and Thrombopenia
| Article | Year |
|---|---|
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Contraindications; Drug-Related Side Effects and Adverse Rea | 2014 |
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Cell Count; Female; Humans; Hydroxyurea | 2015 |
Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Administration Schedule; Female; Hydroxyure | 2010 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1984 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
Combination chemotherapy of advanced lung cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1976 |
A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Thera | 1975 |
[Therapy of chronic myeloid leukemia with interferon, alone or combined. Preliminary experience].
Topics: Adolescent; Adult; Aged; Busulfan; Combined Modality Therapy; Female; Humans; Hydroxyurea; Immunolog | 1991 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
Topics: Adult; Aged; Blood Urea Nitrogen; Chondrosarcoma; Clinical Trials as Topic; Depression, Chemical; DN | 1970 |
34 other studies available for hydroxyurea and Thrombopenia
| Article | Year |
|---|---|
Topics: Adult; Aged; Anemia; Bone Marrow; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myelo | 2022 |
Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.
Topics: Humans; Hydroxyurea; Infant; Primary Myelofibrosis; Remission, Spontaneous; Steroids; Thrombocytopen | 2023 |
Acute myocardial infarction in a patient with chronic myelocytic leukemia during chemotherapy with hydroxyurea.
Topics: Angioplasty, Balloon, Coronary; Anterior Wall Myocardial Infarction; Antineoplastic Agents; Aspirin; | 2010 |
Non-ST-segment elevation myocardial infarction in a patient with essential thrombocythemia treated with glycoprotein IIb/IIIa inhibitor: a case report.
Topics: Electrocardiography; Enzyme Inhibitors; Humans; Hydroxyurea; Male; Middle Aged; Myocardial Infarctio | 2011 |
Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency.
Topics: Aged, 80 and over; Diagnosis, Differential; Humans; Hydroxyurea; Leg; Leg Ulcer; Male; Saphenous Vei | 2012 |
Intracranial hypertension: was it really idiopathic?
Topics: Acetazolamide; Adult; Anticoagulants; Anticonvulsants; Diagnosis, Differential; Drug Therapy, Combin | 2011 |
Hydroxyurea treatment of children with hemoglobin SC disease.
Topics: Acute Chest Syndrome; Adolescent; Antisickling Agents; Child; Child, Preschool; Female; Hemoglobin S | 2013 |
Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Hemolysis; Hemolytic-Uremic Syndrome; Humans; | 2003 |
Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia.
Topics: Adult; Aged; Agglutinins; Anticoagulants; Artifacts; Autoantibodies; Citric Acid; Diagnosis, Differe | 2003 |
HYDROXYUREA (NSC-32065): RESULTS OF A PHASE I STUDY.
Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Drug Therapy; Hydroxyurea; Leukopenia; Statistics a | 1964 |
PEDIATRIC CLINICAL TRIALS WITH HYDROXYUREA (NSC-32065).
Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukemia; Neop | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: UROLOGIC AND GYNECOLOGIC NEOPLASMS.
Topics: Adenocarcinoma; Anemia; Anemia, Aplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Ther | 1964 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Hydroxyurea; Leukopenia; Lymphoma; Lymphoma, L | 1964 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression | 2004 |
Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Deferiprone; Drug Therapy, Combination; Humans; Hydrox | 2006 |
Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms.
Topics: Aged; Arm; Diagnosis, Differential; Drug Eruptions; Humans; Hydroxyurea; Leg Ulcer; Male; Nucleic Ac | 2006 |
Treatment of malignant melanoma with hydroxyurea.
Topics: Adult; Aged; Female; Humans; Hydroxyurea; Leukopenia; Male; Melanoma; Middle Aged; Neoplasm Metastas | 1967 |
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug | 1983 |
Treatment of polycythemia vera with hydroxyurea.
Topics: Acute Disease; Aged; Bone Marrow; Female; Humans; Hydroxyurea; Leukemia; Leukopenia; Male; Middle Ag | 1984 |
Macromegakaryocytosis after hydroxyurea (41490).
Topics: Animals; Blood Platelets; Cell Count; Cell Survival; Female; Hydroxyurea; Immune Sera; Megakaryocyte | 1982 |
Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization.
Topics: Administration, Oral; Bone Marrow; Drug Administration Schedule; Half-Life; Humans; Hydroxyurea; Inf | 1980 |
Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia.
Topics: Adult; Aged; Bone Marrow Diseases; Busulfan; Combined Modality Therapy; Female; Humans; Hydroxyurea; | 1994 |
Gancyclovir-induced megakaryocyte loss in chronic myelogenous leukemia post bone-marrow transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow; Bone Marrow Transplantation | 1996 |
[Treatment of essential thrombocytopenia associated with severe renal insufficiency].
Topics: Humans; Hydroxyurea; Male; Middle Aged; Renal Insufficiency; Severity of Illness Index; Thrombocytop | 1996 |
Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Topics: Administration, Oral; Alanine Transaminase; Animals; Azepines; Blood Platelets; Chemical and Drug In | 1997 |
Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea.
Topics: Aged; Humans; Hydroxyurea; Hyperpigmentation; Male; Nail Diseases; Thrombocytopenia | 1999 |
Severe reaction to hydroxyurea.
Topics: Drug Hypersensitivity; Humans; Hydroxyurea; Male; Middle Aged; Psoriasis; Thrombocytopenia | 1977 |
Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia.
Topics: Busulfan; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count; Leukocytosis; Mitobronitol; Splen | 1975 |
Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide.
Topics: Adult; Cardiomegaly; Eosinophilia; Etoposide; Humans; Hydroxyurea; Male; Syndrome; Thrombocytopenia | 1991 |
Cisplatin preceded by concurrent cytarabine and hydroxyurea: a pilot study based on an in vitro model.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; DNA Repair; Drug | 1990 |
Megakaryocyte size and ploidy in thrombocytopenic or megakaryocytopenic mice.
Topics: Anemia; Animals; Blood Platelets; Hydroxyurea; Immune Sera; Megakaryocytes; Mice; Mice, Mutant Strai | 1990 |
Psoriasis with hydroxyurea. An 18-month study of 60 patients.
Topics: Adult; Aged; Anemia; Chemical and Drug Induced Liver Injury; Drug Resistance; Female; Humans; Hydrox | 1973 |
Investigational drugs for the treatment of malignant melanoma.
Topics: Alkylating Agents; Amides; Anorexia Nervosa; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; | 1974 |
Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
Topics: Administration, Oral; Adult; Amides; Female; Humans; Hydroxyurea; Imidazoles; Injections, Intravenou | 1971 |